{
  "schema_version": "0.1.0",
  "case_id": "HR-ML020",
  "record_classification": {
    "synthetic": true,
    "banner": "SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD",
    "real_historical_name": true,
    "public_release_status": "draft"
  },
  "identity": {
    "person_id": "ML020",
    "display_name": "Yul Brynner",
    "aliases": [
      "Yuliy Borisovich Bryner",
      "Taidje Khan"
    ],
    "sex": "male",
    "era": "Mid-Late 20th Century",
    "nationality": "Russian-born American",
    "historical_dates": {
      "birth": {
        "preferred": {
          "iso": "1920-07-11",
          "display": "July 11, 1920",
          "precision": "day",
          "calendar": "gregorian"
        },
        "alternatives": [
          {
            "date": {
              "iso": "1920",
              "display": "1920",
              "precision": "year",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0008"
            ],
            "resolution_status": "preferred",
            "note": "Roster year agrees with the documented date."
          },
          {
            "date": {
              "iso": "1915-07-11",
              "display": "July 11, 1915",
              "precision": "day",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0001"
            ],
            "resolution_status": "conflicting",
            "note": "One of his own accounts (with Sakhalin as the birthplace), reported by UPI; contradicted by his documented birth in Vladivostok in 1920 and his age of 65 at death."
          },
          {
            "date": {
              "iso": "1915-07-12",
              "display": "July 12, 1915",
              "precision": "day",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0007"
            ],
            "resolution_status": "conflicting",
            "note": "Given in a film reference under the name Taidje Kahn; rejected for the same reasons."
          }
        ]
      },
      "death": {
        "preferred": {
          "iso": "1985-10-10",
          "display": "October 10, 1985",
          "precision": "day",
          "calendar": "gregorian"
        },
        "alternatives": [
          {
            "date": {
              "iso": "1985",
              "display": "1985",
              "precision": "year",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0008"
            ],
            "resolution_status": "preferred",
            "note": "Roster year agrees with the cited sources."
          }
        ]
      }
    },
    "synthetic_identity": {
      "mrn": "HR-ML020-SYN",
      "ssn": "000-20-4572",
      "date_of_birth": "1963-07-11",
      "name_policy": "real_historical_name",
      "fictional_facility": "St. Posthumous Health Center",
      "fictional_primary_clinician": "Simon Achterberg, MD",
      "fictional_consultant": {
        "name": "Leah Morrow, MD",
        "specialty": "Thoracic Oncology"
      }
    }
  },
  "historical_timeline": [
    {
      "event_id": "EVT-0001",
      "date": {
        "iso": "1920-07-11",
        "display": "July 11, 1920",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Born in Vladivostok, by the documented account; he later gave other birthplaces and years.",
      "claim_ids": [
        "CLM-0001",
        "CLM-0002"
      ]
    },
    {
      "event_id": "EVT-0002",
      "date": {
        "iso": "1951",
        "display": "1951",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "First plays the King in The King and I on Broadway; Academy Award for the 1956 film.",
      "claim_ids": [
        "CLM-0003"
      ]
    },
    {
      "event_id": "EVT-0003",
      "date": {
        "iso": "1971",
        "display": "1971",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Quits smoking after decades of heavy use.",
      "claim_ids": [
        "CLM-0004"
      ]
    },
    {
      "event_id": "EVT-0004",
      "date": {
        "iso": "1983-09",
        "display": "September 1983",
        "precision": "month",
        "calendar": "gregorian"
      },
      "summary": "Found to have lung cancer that cannot be removed surgically; treated that month and vows to resume touring.",
      "claim_ids": [
        "CLM-0005"
      ]
    },
    {
      "event_id": "EVT-0005",
      "date": {
        "iso": "1985",
        "display": "summer 1985",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Last performance as the King in New York, about two years after the diagnosis.",
      "claim_ids": [
        "CLM-0006",
        "CLM-0007"
      ]
    },
    {
      "event_id": "EVT-0006",
      "date": {
        "iso": "1985-10-10",
        "display": "October 10, 1985",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Dies in New York at 65 of complications of cancer; an anti-smoking message he recorded is broadcast after his death.",
      "claim_ids": [
        "CLM-0008",
        "CLM-0009"
      ]
    }
  ],
  "claims": [
    {
      "claim_id": "CLM-0001",
      "statement": "Yul Brynner was born Yuliy Borisovich Bryner on July 11, 1920, in Vladivostok, Russia.",
      "evidence_grade": "D",
      "certainty": "probable",
      "clinical_interpretation": "The documented date used for the synthetic date of birth; it agrees with his age of 65 at death in contemporary obituaries. He gave other accounts himself (see CLM-0002).",
      "source_links": [
        {
          "source_id": "SRC-0006",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0005",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0002",
      "statement": "He gave varying accounts of his origins, saying at times that he was born on Sakhalin Island, with the year given as 1915 (UPI gives July 11, 1915; another reference gives July 12, 1915, under the name Taidje Kahn).",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "The conflicting accounts are his own; they are recorded as rejected alternatives to the documented date.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0007",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0005",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0003",
      "statement": "He first played the King of Siam in The King and I on Broadway in 1951, won the Academy Award for best actor in the 1956 film, and played the role 4,625 times over 34 years.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Used for the synthetic modern occupation (stage actor and singer on tour).",
      "source_links": [
        {
          "source_id": "SRC-0006",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0005",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0004",
      "statement": "He smoked heavily for decades: UPI reported that at one time he smoked five packs of cigarettes a day, and Cancer Today reports two to four packs a day from the age of 12 and that he quit in 1971.",
      "evidence_grade": "D",
      "certainty": "probable",
      "clinical_interpretation": "The amounts differ between sources; the quit year is from one source. Used for the former-smoker history; the pack-year estimate in the modern record is synthetic.",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0004",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": true
    },
    {
      "claim_id": "CLM-0005",
      "statement": "In September 1983 he was found to have lung cancer; Cancer Today reports that he had found a lump on his vocal cords and that the tumor was too close to his heart for surgery, and UPI reports that he was treated for lung cancer that month and said he would beat the disease and resume touring.",
      "evidence_grade": "D",
      "certainty": "probable",
      "clinical_interpretation": "The diagnosis month and the inoperable tumor are consistent across sources; the voice complaint and the place of treatment are from single sources. Anchors the synthetic presentation with hoarseness and an unresectable left upper lobe cancer.",
      "source_links": [
        {
          "source_id": "SRC-0004",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0006",
      "statement": "He returned to the stage and kept playing the King for about two more years; his last performance came in New York in the summer of 1985, less than four months before his death.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "UPI gives July 2 for the farewell performance; other accounts give June 30. The case uses summer 1985. Used for the goal of supporting him to keep working.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0005",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0007",
      "statement": "He said in an interview that he believed his cancer was directly caused by smoking, calling smoking \"suicide.\"",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "His own public statement.",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": true
    },
    {
      "claim_id": "CLM-0008",
      "statement": "After his death the American Cancer Society released a 30-second television message taken from a January 1985 Good Morning America interview, in which he says: \"Now that I'm gone, I tell you: Don't smoke, whatever you do. Just don't smoke.\"",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "UPI reports that it first aired on ABC in February 1986, about four months after his death; Cancer Today says networks ran it within days of his death. The case records both and uses neither date in the episode.",
      "source_links": [
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0004",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0007",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": true
    },
    {
      "claim_id": "CLM-0009",
      "statement": "He died on October 10, 1985, at 65, at New York Hospital-Cornell Medical Center, of complications of cancer.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History only; after the true-frame episode.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0006",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0005",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    }
  ],
  "sources": [
    {
      "source_id": "SRC-0001",
      "title": "Yul Brynner, exotic actor (obituary)",
      "publisher": "United Press International",
      "url": "https://www.upi.com/Archives/1985/10/10/Yul-Brynner-exotic-actor/4761497764800/",
      "source_type": "other",
      "published": "1985-10-10",
      "accessed": "2026-11-03",
      "rights_note": "Wire-service obituary; facts used with citation."
    },
    {
      "source_id": "SRC-0002",
      "title": "Brynner's final bow",
      "publisher": "United Press International",
      "url": "https://www.upi.com/Archives/1985/10/10/Brynners-final-bow/6906497764800/",
      "source_type": "other",
      "published": "1985-10-10",
      "accessed": "2026-11-03",
      "rights_note": "Wire-service report quoting him; facts used with citation."
    },
    {
      "source_id": "SRC-0003",
      "title": "'Don't smoke, whatever you do'",
      "publisher": "United Press International",
      "url": "https://www.upi.com/Archives/1986/02/19/Dont-smoke-whatever-you-do/5599509173200/",
      "source_type": "other",
      "published": "1986-02-19",
      "accessed": "2026-11-03",
      "rights_note": "Wire-service report on the American Cancer Society message; quoted briefly with citation."
    },
    {
      "source_id": "SRC-0004",
      "title": "Rochman S. Yul Brynner (Cancer Today)",
      "publisher": "American Association for Cancer Research",
      "url": "https://cancertodaymag.org/?p=547",
      "source_type": "other",
      "published": "2011-12-05",
      "accessed": "2026-11-03",
      "rights_note": "Magazine feature; facts used with citation."
    },
    {
      "source_id": "SRC-0005",
      "title": "Milestones, Oct. 21, 1985",
      "publisher": "TIME",
      "url": "https://time.com/archive/6705008/milestones-oct-21-1985-4/",
      "source_type": "other",
      "published": "1985-10-21",
      "accessed": "2026-11-03",
      "rights_note": "Magazine notice; facts used with citation."
    },
    {
      "source_id": "SRC-0006",
      "title": "Yul Brynner",
      "publisher": "Biography.com (A&E Television Networks)",
      "url": "https://www.biography.com/actors/yul-brynner",
      "source_type": "biography",
      "published": "undated",
      "accessed": "2026-11-03",
      "rights_note": "Reference biography; facts used with citation."
    },
    {
      "source_id": "SRC-0007",
      "title": "Brynner, Yul",
      "publisher": "Encyclopedia.com (International Dictionary of Films and Filmmakers)",
      "url": "https://www.encyclopedia.com/movies/dictionaries-thesauruses-pictures-and-press-releases/brynner-yul",
      "source_type": "biography",
      "published": "undated",
      "accessed": "2026-11-03",
      "rights_note": "Reference entry; facts used with citation."
    },
    {
      "source_id": "SRC-0008",
      "title": "HISTMED Master Roster v3",
      "publisher": "The Human Record project",
      "url": "https://humanrecord.example.org/internal/HISTMED_Master_Roster_v3.xlsx",
      "source_type": "other",
      "published": "2026-11-03",
      "accessed": "2026-11-03",
      "rights_note": "Internal source locator; inherited claims remain provisional until corroborated."
    }
  ],
  "synthetic_episode": {
    "calendar_frame": "modern_shifted",
    "index_date": "2026-09-01",
    "index_age": 63,
    "date_shift_policy": "HR-DATE-SHIFT-1",
    "teaching_objective": "Work up hoarseness from left vocal fold paralysis in a 63-year-old former heavy smoker to a tissue diagnosis of advanced nonsquamous non-small cell lung cancer; stage it with PET-CT and brain MRI; obtain PD-L1 and comprehensive tissue and plasma biomarker testing before choosing first-line systemic therapy (pembrolizumab for PD-L1 70 percent with no actionable alteration); monitor for immune-related adverse events with TSH, free T4, liver tests, glucose, and cortisol as indicated, and evaluate a rash on treatment; start a bone-modifying agent safely; integrate palliative care early (ASCO 2017) with symptom and distress screening; record the tobacco history; begin advance care planning; and support his wish to keep performing, on the CMID lung cancer schedule and NCCN guidance.",
    "visit_schedule": [
      {
        "encounter_id": "ENC-001",
        "date": "2026-09-01",
        "purpose": "New patient visit for six weeks of hoarseness, with a left upper lobe mass on same-day CT"
      },
      {
        "encounter_id": "ENC-002",
        "date": "2026-09-15",
        "purpose": "Diagnosis and staging review with thoracic oncology consultation"
      },
      {
        "encounter_id": "ENC-003",
        "date": "2026-09-22",
        "purpose": "Biomarker results and start of first-line pembrolizumab"
      },
      {
        "encounter_id": "ENC-004",
        "date": "2026-10-13",
        "purpose": "Cycle 2 review: immune-related adverse event monitoring, symptoms, and return to work"
      },
      {
        "encounter_id": "ENC-005",
        "date": "2026-10-20",
        "purpose": "Same-day sick visit for an itchy rash on pembrolizumab"
      },
      {
        "encounter_id": "ENC-006",
        "date": "2026-10-27",
        "purpose": "Periodic adult preventive visit"
      }
    ]
  },
  "clinical": {
    "problems": [
      {
        "id": "PRB-001",
        "display": "Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notes",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "C34.12",
            "display": "Malignant neoplasm of upper lobe, left bronchus or lung",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic modern histology, stage, and biomarkers linked to his documented inoperable lung cancer of September 1983.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "both_with_link",
        "recorded_date": "2026-09-15"
      },
      {
        "id": "PRB-002",
        "display": "Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compression",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "C79.51",
            "display": "Secondary malignant neoplasm of bone",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic metastatic sites chosen so that first-line systemic therapy is the standard of care; no source describes the spread of his cancer.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "recorded_date": "2026-09-15"
      },
      {
        "id": "PRB-003",
        "display": "Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary window",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "J38.01",
            "display": "Paralysis of vocal cords and larynx, unilateral",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic laryngoscopy finding anchored to the published account that a vocal-cord problem led to his diagnosis; the lay 'lump on his vocal cords' is not modeled as a laryngeal tumor.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "both_with_link"
      },
      {
        "id": "PRB-004",
        "display": "Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosis",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "R91.8",
            "display": "Other nonspecific abnormal finding of lung field",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic presenting imaging finding, recorded before the tissue diagnosis.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active"
      },
      {
        "id": "PRB-005",
        "display": "Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco since",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "Z87.891",
            "display": "Personal history of nicotine dependence",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004",
            "CLM-0007"
          ],
          "synthetic_reason": "Synthetic modern entry linked to the documented heavy smoking and quitting; the pack-year figure is a synthetic midpoint of conflicting published amounts.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "both_with_link"
      },
      {
        "id": "PRB-006",
        "display": "Immune-related maculopapular rash from pembrolizumab, grade 1 (about 8 percent of body surface area, itchy, no blisters or mucosal involvement)",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "L27.0",
            "display": "Generalized skin eruption due to drugs and medicaments taken internally",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic common immune-related adverse event on checkpoint inhibitor therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "recorded_date": "2026-10-20"
      }
    ],
    "medications": [
      {
        "id": "MED-001",
        "display": "Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeks",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "1657750",
            "display": "4 ML pembrolizumab 25 MG/ML Injection",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "dose": {
          "value": 200,
          "unit": "mg"
        },
        "route": "intravenous",
        "frequency": {
          "period": 3,
          "period_unit": "wk",
          "text": "Every 3 weeks in the oncology infusion unit, after the immune-related adverse event laboratory panel"
        },
        "start_date": "2026-09-22",
        "indication_problem_ids": [
          "PRB-001"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic NCCN first-line therapy for advanced nonsquamous NSCLC with PD-L1 TPS 50 percent or more and no actionable alteration; chosen with him as monotherapy to spare the toxicity of chemotherapy while he works toward returning to the stage.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "MED-002",
        "display": "Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every 12 weeks, for bone metastases",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "1114085",
            "display": "100 ML zoledronic acid 0.04 MG/ML Injection",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "dose": {
          "value": 4,
          "unit": "mg"
        },
        "route": "intravenous",
        "frequency": {
          "period": 12,
          "period_unit": "wk",
          "text": "Every 12 weeks, after calcium and creatinine, with a dental examination done first"
        },
        "start_date": "2026-10-13",
        "indication_problem_ids": [
          "PRB-002"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic bone-modifying agent for bone metastases from lung cancer, at the every-12-week interval, started after the dental examination.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "MED-003",
        "display": "Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet daily, with calcium from food, while on zoledronic acid",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "199362",
            "display": "cholecalciferol 0.025 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "dose": {
          "value": 25,
          "unit": "ug"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet by mouth daily"
        },
        "start_date": "2026-10-13",
        "indication_problem_ids": [
          "PRB-002"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vitamin D supplement to prevent hypocalcemia on a bone-modifying agent.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "MED-004",
        "display": "Triamcinolone acetonide 0.1% cream, thin layer to the rash twice daily for two weeks (not on the face or skin folds)",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "1014314",
            "display": "triamcinolone acetonide 1 MG/ML Topical Cream",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "{application}"
        },
        "route": "topical",
        "frequency": {
          "period": 12,
          "period_unit": "h",
          "text": "Apply a thin layer twice daily for up to two weeks"
        },
        "start_date": "2026-10-20",
        "indication_problem_ids": [
          "PRB-006"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic medium-potency topical steroid for a grade 1 immune-related rash, per ASCO 2021.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "MED-005",
        "display": "Cetirizine 10 mg oral tablet, one tablet daily as needed for itching",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "1014678",
            "display": "cetirizine hydrochloride 10 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "dose": {
          "value": 10,
          "unit": "mg"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet by mouth daily as needed for itching"
        },
        "start_date": "2026-10-20",
        "indication_problem_ids": [
          "PRB-006"
        ],
        "as_needed": true,
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic non-sedating antihistamine for itching.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      }
    ],
    "allergies": [
      {
        "id": "ALG-001",
        "display": "No known allergy",
        "status": "active",
        "assertion": "no_known_allergy",
        "substance": {
          "system": "http://snomed.info/sct",
          "code": "716186003",
          "display": "No known allergy"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic allergy assertion for EHR completeness; not a historical assertion.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      }
    ],
    "observations": [
      {
        "id": "OBS-HGB-V1",
        "display": "Hemoglobin [Mass/volume] in Blood",
        "label": "Hemoglobin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-01",
        "value": 13.8,
        "unit": "g/dL",
        "reference_range": {
          "low": 13.5,
          "high": 17.5
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "718-7",
            "display": "Hemoglobin [Mass/volume] in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline blood count and chemistry at presentation; normal calcium and alkaline phosphatase despite bone lesions found later.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-WBC-V1",
        "display": "Leukocytes [#/volume] in Blood by Automated count",
        "label": "White cell count",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-01",
        "value": 7.9,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 4.0,
          "high": 11.0
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6690-2",
            "display": "Leukocytes [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline blood count and chemistry at presentation; normal calcium and alkaline phosphatase despite bone lesions found later.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-PLT-V1",
        "display": "Platelets [#/volume] in Blood by Automated count",
        "label": "Platelets",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-01",
        "value": 290,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 150,
          "high": 400
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "777-3",
            "display": "Platelets [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline blood count and chemistry at presentation; normal calcium and alkaline phosphatase despite bone lesions found later.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-NA-V1",
        "display": "Sodium [Moles/volume] in Serum or Plasma",
        "label": "Sodium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-01",
        "value": 138,
        "unit": "mmol/L",
        "reference_range": {
          "low": 135,
          "high": 145
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2951-2",
            "display": "Sodium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline blood count and chemistry at presentation; normal calcium and alkaline phosphatase despite bone lesions found later.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-K-V1",
        "display": "Potassium [Moles/volume] in Serum or Plasma",
        "label": "Potassium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-01",
        "value": 4.3,
        "unit": "mmol/L",
        "reference_range": {
          "low": 3.5,
          "high": 5.1
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2823-3",
            "display": "Potassium [Moles/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline blood count and chemistry at presentation; normal calcium and alkaline phosphatase despite bone lesions found later.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-CREAT-V1",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-01",
        "value": 0.9,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.7,
          "high": 1.3
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline blood count and chemistry at presentation; normal calcium and alkaline phosphatase despite bone lesions found later.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V1",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-01",
        "value": 92,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline blood count and chemistry at presentation; normal calcium and alkaline phosphatase despite bone lesions found later.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-CA-V1",
        "display": "Calcium [Mass/volume] in Serum or Plasma",
        "label": "Calcium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-01",
        "value": 9.6,
        "unit": "mg/dL",
        "reference_range": {
          "low": 8.6,
          "high": 10.3
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "17861-6",
            "display": "Calcium [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline blood count and chemistry at presentation; normal calcium and alkaline phosphatase despite bone lesions found later.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALB-V1",
        "display": "Albumin [Mass/volume] in Serum or Plasma",
        "label": "Albumin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-01",
        "value": 4.0,
        "unit": "g/dL",
        "reference_range": {
          "low": 3.5,
          "high": 5.0
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1751-7",
            "display": "Albumin [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline blood count and chemistry at presentation; normal calcium and alkaline phosphatase despite bone lesions found later.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V1",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-01",
        "value": 24,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 55
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline blood count and chemistry at presentation; normal calcium and alkaline phosphatase despite bone lesions found later.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V1",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-01",
        "value": 22,
        "unit": "U/L",
        "reference_range": {
          "low": 8,
          "high": 48
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline blood count and chemistry at presentation; normal calcium and alkaline phosphatase despite bone lesions found later.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALP-V1",
        "display": "Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "Alkaline phosphatase",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-01",
        "value": 98,
        "unit": "U/L",
        "reference_range": {
          "low": 40,
          "high": 129
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6768-6",
            "display": "Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline blood count and chemistry at presentation; normal calcium and alkaline phosphatase despite bone lesions found later.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-TBIL-V1",
        "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
        "label": "Total bilirubin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-01",
        "value": 0.6,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.1,
          "high": 1.2
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1975-2",
            "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline blood count and chemistry at presentation; normal calcium and alkaline phosphatase despite bone lesions found later.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-GLU-V1",
        "display": "Glucose [Mass/volume] in Serum or Plasma",
        "label": "Glucose",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-01",
        "value": 96,
        "unit": "mg/dL",
        "reference_range": {
          "low": 70,
          "high": 99
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2345-7",
            "display": "Glucose [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline blood count and chemistry at presentation; normal calcium and alkaline phosphatase despite bone lesions found later.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ9-V1",
        "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
        "label": "PHQ-9",
        "status": "final",
        "effective_date": "2026-09-01",
        "value": 5,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "44261-6",
            "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic mild depressive symptoms while awaiting tests; item 9 scored 0.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-ESAS-V2",
        "display": "Total score [Edmonton Symptom Assessment System]",
        "label": "ESAS total symptom distress score",
        "status": "final",
        "effective_date": "2026-09-15",
        "value": 18,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "112493-2",
            "display": "Total score [Edmonton Symptom Assessment System]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic Edmonton Symptom Assessment System total at diagnosis (tiredness, worry, and hoarseness-related distress).",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-TSH-V3",
        "display": "Thyrotropin [Units/volume] in Serum or Plasma",
        "label": "TSH",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-22",
        "value": 2.1,
        "unit": "m[IU]/L",
        "reference_range": {
          "low": 0.4,
          "high": 4.0
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "3016-3",
            "display": "Thyrotropin [Units/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline laboratory panel before the first immune checkpoint inhibitor dose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-FT4-V3",
        "display": "Thyroxine (T4) free [Mass/volume] in Serum or Plasma",
        "label": "Free T4",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-22",
        "value": 1.2,
        "unit": "ng/dL",
        "reference_range": {
          "low": 0.8,
          "high": 1.8
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "3024-7",
            "display": "Thyroxine (T4) free [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline laboratory panel before the first immune checkpoint inhibitor dose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-CORT-V3",
        "display": "Cortisol [Mass/volume] in Serum or Plasma",
        "label": "Morning cortisol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-22",
        "value": 14.2,
        "unit": "ug/dL",
        "reference_range": {
          "low": 5,
          "high": 23,
          "text": "Morning (8 a.m.) reference interval"
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2143-6",
            "display": "Cortisol [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline laboratory panel before the first immune checkpoint inhibitor dose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V3",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-22",
        "value": 26,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 55
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline laboratory panel before the first immune checkpoint inhibitor dose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V3",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-22",
        "value": 23,
        "unit": "U/L",
        "reference_range": {
          "low": 8,
          "high": 48
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline laboratory panel before the first immune checkpoint inhibitor dose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALP-V3",
        "display": "Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "Alkaline phosphatase",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-22",
        "value": 101,
        "unit": "U/L",
        "reference_range": {
          "low": 40,
          "high": 129
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6768-6",
            "display": "Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline laboratory panel before the first immune checkpoint inhibitor dose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-TBIL-V3",
        "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
        "label": "Total bilirubin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-22",
        "value": 0.6,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.1,
          "high": 1.2
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1975-2",
            "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline laboratory panel before the first immune checkpoint inhibitor dose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-CREAT-V3",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-22",
        "value": 0.9,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.7,
          "high": 1.3
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline laboratory panel before the first immune checkpoint inhibitor dose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V3",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-22",
        "value": 92,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline laboratory panel before the first immune checkpoint inhibitor dose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-GLU-V3",
        "display": "Glucose [Mass/volume] in Serum or Plasma",
        "label": "Glucose",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-22",
        "value": 94,
        "unit": "mg/dL",
        "reference_range": {
          "low": 70,
          "high": 99
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2345-7",
            "display": "Glucose [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline laboratory panel before the first immune checkpoint inhibitor dose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-CA-V3",
        "display": "Calcium [Mass/volume] in Serum or Plasma",
        "label": "Calcium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-22",
        "value": 9.5,
        "unit": "mg/dL",
        "reference_range": {
          "low": 8.6,
          "high": 10.3
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "17861-6",
            "display": "Calcium [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline laboratory panel before the first immune checkpoint inhibitor dose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-HGB-V3",
        "display": "Hemoglobin [Mass/volume] in Blood",
        "label": "Hemoglobin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-22",
        "value": 13.6,
        "unit": "g/dL",
        "reference_range": {
          "low": 13.5,
          "high": 17.5
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "718-7",
            "display": "Hemoglobin [Mass/volume] in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline laboratory panel before the first immune checkpoint inhibitor dose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-WBC-V3",
        "display": "Leukocytes [#/volume] in Blood by Automated count",
        "label": "White cell count",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-22",
        "value": 7.6,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 4.0,
          "high": 11.0
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6690-2",
            "display": "Leukocytes [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline laboratory panel before the first immune checkpoint inhibitor dose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-PLT-V3",
        "display": "Platelets [#/volume] in Blood by Automated count",
        "label": "Platelets",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-09-22",
        "value": 284,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 150,
          "high": 400
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "777-3",
            "display": "Platelets [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baseline laboratory panel before the first immune checkpoint inhibitor dose.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-TSH-V4",
        "display": "Thyrotropin [Units/volume] in Serum or Plasma",
        "label": "TSH",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-13",
        "value": 2.4,
        "unit": "m[IU]/L",
        "reference_range": {
          "low": 0.4,
          "high": 4.0
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "3016-3",
            "display": "Thyrotropin [Units/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic laboratory panel before cycle 2; fasting glucose slightly above range was non-fasting (mid-morning).",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-FT4-V4",
        "display": "Thyroxine (T4) free [Mass/volume] in Serum or Plasma",
        "label": "Free T4",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-13",
        "value": 1.1,
        "unit": "ng/dL",
        "reference_range": {
          "low": 0.8,
          "high": 1.8
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "3024-7",
            "display": "Thyroxine (T4) free [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic laboratory panel before cycle 2; fasting glucose slightly above range was non-fasting (mid-morning).",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V4",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-13",
        "value": 30,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 55
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic laboratory panel before cycle 2; fasting glucose slightly above range was non-fasting (mid-morning).",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V4",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-13",
        "value": 27,
        "unit": "U/L",
        "reference_range": {
          "low": 8,
          "high": 48
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic laboratory panel before cycle 2; fasting glucose slightly above range was non-fasting (mid-morning).",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-TBIL-V4",
        "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
        "label": "Total bilirubin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-13",
        "value": 0.7,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.1,
          "high": 1.2
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1975-2",
            "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic laboratory panel before cycle 2; fasting glucose slightly above range was non-fasting (mid-morning).",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-CREAT-V4",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-13",
        "value": 0.9,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.7,
          "high": 1.3
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic laboratory panel before cycle 2; fasting glucose slightly above range was non-fasting (mid-morning).",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V4",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-13",
        "value": 92,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic laboratory panel before cycle 2; fasting glucose slightly above range was non-fasting (mid-morning).",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-GLU-V4",
        "display": "Glucose [Mass/volume] in Serum or Plasma",
        "label": "Glucose",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-13",
        "value": 104,
        "unit": "mg/dL",
        "reference_range": {
          "low": 70,
          "high": 99
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2345-7",
            "display": "Glucose [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic laboratory panel before cycle 2; fasting glucose slightly above range was non-fasting (mid-morning).",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-CA-V4",
        "display": "Calcium [Mass/volume] in Serum or Plasma",
        "label": "Calcium",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-13",
        "value": 9.4,
        "unit": "mg/dL",
        "reference_range": {
          "low": 8.6,
          "high": 10.3
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "17861-6",
            "display": "Calcium [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic laboratory panel before cycle 2; fasting glucose slightly above range was non-fasting (mid-morning).",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-HGB-V4",
        "display": "Hemoglobin [Mass/volume] in Blood",
        "label": "Hemoglobin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-13",
        "value": 13.5,
        "unit": "g/dL",
        "reference_range": {
          "low": 13.5,
          "high": 17.5
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "718-7",
            "display": "Hemoglobin [Mass/volume] in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic laboratory panel before cycle 2; fasting glucose slightly above range was non-fasting (mid-morning).",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-WBC-V4",
        "display": "Leukocytes [#/volume] in Blood by Automated count",
        "label": "White cell count",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-13",
        "value": 7.2,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 4.0,
          "high": 11.0
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6690-2",
            "display": "Leukocytes [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic laboratory panel before cycle 2; fasting glucose slightly above range was non-fasting (mid-morning).",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-PLT-V4",
        "display": "Platelets [#/volume] in Blood by Automated count",
        "label": "Platelets",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-13",
        "value": 270,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 150,
          "high": 400
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "777-3",
            "display": "Platelets [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic laboratory panel before cycle 2; fasting glucose slightly above range was non-fasting (mid-morning).",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-ESAS-V4",
        "display": "Total score [Edmonton Symptom Assessment System]",
        "label": "ESAS total symptom distress score",
        "status": "final",
        "effective_date": "2026-10-13",
        "value": 12,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "112493-2",
            "display": "Total score [Edmonton Symptom Assessment System]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic symptom score three weeks into treatment.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ9-V4",
        "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
        "label": "PHQ-9",
        "status": "final",
        "effective_date": "2026-10-13",
        "value": 4,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "44261-6",
            "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic mood rescreen during active treatment; item 9 scored 0.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-TSH-SICK",
        "display": "Thyrotropin [Units/volume] in Serum or Plasma",
        "label": "TSH",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-20",
        "value": 2.6,
        "unit": "m[IU]/L",
        "reference_range": {
          "low": 0.4,
          "high": 4.0
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "3016-3",
            "display": "Thyrotropin [Units/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic check for other immune-related adverse events at the rash visit.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-FT4-SICK",
        "display": "Thyroxine (T4) free [Mass/volume] in Serum or Plasma",
        "label": "Free T4",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-20",
        "value": 1.1,
        "unit": "ng/dL",
        "reference_range": {
          "low": 0.8,
          "high": 1.8
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "3024-7",
            "display": "Thyroxine (T4) free [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic check for other immune-related adverse events at the rash visit.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-SICK",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-20",
        "value": 28,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 55
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic check for other immune-related adverse events at the rash visit.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-SICK",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-20",
        "value": 25,
        "unit": "U/L",
        "reference_range": {
          "low": 8,
          "high": 48
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic check for other immune-related adverse events at the rash visit.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-TBIL-SICK",
        "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
        "label": "Total bilirubin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-20",
        "value": 0.6,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.1,
          "high": 1.2
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1975-2",
            "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic check for other immune-related adverse events at the rash visit.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-CREAT-SICK",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-20",
        "value": 0.9,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.7,
          "high": 1.3
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic check for other immune-related adverse events at the rash visit.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-EOS-SICK",
        "display": "Eosinophils [#/volume] in Blood by Automated count",
        "label": "Eosinophils",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-20",
        "value": 0.62,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 0.0,
          "high": 0.5
        },
        "interpretation": "H",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "711-2",
            "display": "Eosinophils [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic mild eosinophilia, common with immune-related skin reactions.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ2-PREV",
        "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
        "label": "PHQ-2",
        "status": "final",
        "effective_date": "2026-10-27",
        "value": 1,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "55758-7",
            "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic depression screen at the preventive visit; below the threshold.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "OBS-AUDITC-PREV",
        "display": "Total score [AUDIT-C]",
        "label": "AUDIT-C",
        "status": "final",
        "effective_date": "2026-10-27",
        "value": 2,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "75626-2",
            "display": "Total score [AUDIT-C]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic alcohol screen at the preventive visit; below the risk threshold. Not a claim about his real drinking.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      }
    ],
    "procedures": [
      {
        "id": "PROC-001",
        "display": "Flexible laryngoscopy by the ENT surgeon: left vocal fold immobile in the paramedian position with incomplete glottic closure; no laryngeal mass or mucosal lesion",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "49077009",
            "display": "Flexible fiberoptic laryngoscopy",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "period": {
          "start": "2026-09-01",
          "end": "2026-09-01"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic laryngoscopy explaining the hoarseness.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "PROC-002",
        "display": "CT of the chest, abdomen, and pelvis with contrast: 5.2 cm left upper lobe mass invading the mediastinal fat of the aortopulmonary window and abutting the aortic arch and left pulmonary artery; enlarged aortopulmonary window (2.4 cm) and subcarinal (1.8 cm) lymph nodes; a small lytic lesion in the T10 vertebral body; no adrenal or liver lesion",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "433761009",
            "display": "CT of thorax, abdomen and pelvis with contrast",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "period": {
          "start": "2026-09-01",
          "end": "2026-09-01"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic presenting CT.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "PROC-003",
        "display": "FDG PET-CT: avid left upper lobe mass (SUVmax 14) with mediastinal invasion; avid aortopulmonary window and subcarinal nodes (N2); no contralateral or supraclavicular nodes; avid lytic lesions at T10, the right ilium, and the left sixth rib, without fracture (M1c)",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "443271005",
            "display": "Positron emission tomography with computed tomography using fluorodeoxyglucose (18-F)",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "period": {
          "start": "2026-09-04",
          "end": "2026-09-04"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic staging PET-CT.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "PROC-004",
        "display": "MRI of the brain with contrast: no metastases",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "16327691000119101",
            "display": "MRI of brain with contrast",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "period": {
          "start": "2026-09-04",
          "end": "2026-09-04"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic staging brain MRI.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "PROC-005",
        "display": "Endobronchial ultrasound-guided needle aspiration of subcarinal (station 7) and left lower paratracheal (4L) nodes: adenocarcinoma, TTF-1 and napsin A positive; PD-L1 (22C3) tumor proportion score 70 percent; tissue sent for comprehensive next-generation sequencing (reported 12 days later: KRAS G12V and TP53 mutations; no EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14, RET, NTRK, HER2, or NRG1 alteration), with concordant plasma cell-free DNA testing",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "1137699004",
            "display": "Endoscopic endobronchial ultrasonography guided transbronchial needle aspiration of mediastinal lymph node",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "period": {
          "start": "2026-09-09",
          "end": "2026-09-09"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic tissue diagnosis and biomarker testing.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "PROC-006",
        "display": "Outpatient palliative care visit: symptom assessment, coping, goals of care, and a plan for breathlessness and cough",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "103735009",
            "display": "Palliative care",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "period": {
          "start": "2026-09-29",
          "end": "2026-09-29"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic early integrated palliative care visit within eight weeks of diagnosis.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "PROC-007",
        "display": "Office injection medialization of the left vocal fold under laryngoscopic guidance by the ENT surgeon, to improve glottic closure and voice",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "1303718002",
            "display": "Flexible fiberoptic laryngoscopic-guided vocal cord injection",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "period": {
          "start": "2026-10-06",
          "end": "2026-10-06"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic voice-restoring procedure to support his return to the stage.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "PROC-008",
        "display": "Advance care planning conversation, about 30 minutes",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "713603004",
            "display": "Advance care planning",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "period": {
          "start": "2026-10-27",
          "end": "2026-10-27"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic advance care planning; builds on the palliative care team's goals-of-care conversation.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      }
    ],
    "immunizations": [
      {
        "id": "IMM-001",
        "display": "Influenza vaccine, 2025-2026 season",
        "status": "completed",
        "date": "2025-10-21",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "140",
            "display": "Influenza, split virus, trivalent, PF",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic adult immunization history in the modern frame; not a historical assertion.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "IMM-002",
        "display": "Tdap vaccine",
        "status": "completed",
        "date": "2020-03-17",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "115",
            "display": "Tdap",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic immunization history in the modern frame; not a historical assertion.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "IMM-003",
        "display": "Influenza vaccine, 2026-2027 season",
        "status": "completed",
        "date": "2026-10-27",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "140",
            "display": "Influenza, split virus, trivalent, PF",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic yearly inactivated influenza vaccination; safe on checkpoint inhibitor therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "IMM-004",
        "display": "Pneumococcal conjugate vaccine PCV20, single dose",
        "status": "completed",
        "date": "2026-10-27",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "216",
            "display": "Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic single dose recommended for all adults 50 and older.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "IMM-005",
        "display": "Recombinant zoster vaccine, dose 1 of 2",
        "status": "completed",
        "date": "2026-10-27",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "187",
            "display": "zoster recombinant",
            "validation_status": "validated",
            "validated_on": "2026-11-03"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic first dose of the two-dose series recommended from age 50.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      }
    ],
    "family_history": [],
    "past_medical_history": [
      {
        "id": "PMH-001",
        "display": "Heavy cigarette smoking for decades, quit twelve years before the index visit",
        "historical_date": {
          "iso": "1971",
          "display": "1971",
          "precision": "year",
          "calendar": "gregorian"
        },
        "provenance": {
          "evidence_grade": "D",
          "claim_ids": [
            "CLM-0004"
          ],
          "synthetic_reason": null,
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      }
    ],
    "encounters": [
      {
        "id": "ENC-001",
        "display": "New patient visit for six weeks of hoarseness, with a left upper lobe mass on same-day CT",
        "status": "finished",
        "date": "2026-09-01",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "ENC-002",
        "display": "Diagnosis and staging review with thoracic oncology consultation",
        "status": "finished",
        "date": "2026-09-15",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-03"
        },
        "documentation": {
          "chief_complaint": "Diagnosis and staging review",
          "hpi": {
            "narrative": "Mr. Brynner returns two weeks after his first visit. His PET-CT and brain MRI were done eleven days ago, and the endobronchial ultrasound biopsy six days ago. He saw the thoracic oncologist this morning and was told he has adenocarcinoma of the lung that has spread to three bones. His voice is still weak and breathy, and he has not sung since the tour paused. He has a little dry cough in the mornings, no blood in his sputum, and no breathlessness on the level. He has no bone, back, rib, or hip pain, no headache, and no weakness or numbness. His weight is steady. He is sleeping less well with worry, but he says he wants every fact and wants to get back on stage. He has not smoked for 12 years.",
            "elements": [
              {
                "label": "Results since last visit",
                "value": "PET-CT and brain MRI; endobronchial ultrasound biopsy: adenocarcinoma, PD-L1 70 percent; plasma testing without an actionable alteration; tissue sequencing pending"
              },
              {
                "label": "Voice",
                "value": "Weak and breathy; not singing"
              },
              {
                "label": "Respiratory",
                "value": "Morning dry cough; no hemoptysis; no breathlessness on the level"
              },
              {
                "label": "Bone and neurological symptoms",
                "value": "None"
              },
              {
                "label": "Coping",
                "value": "Worried and sleeping less; distress thermometer 6 of 10"
              }
            ]
          },
          "ros": [
            {
              "system": "Respiratory",
              "status": "positive",
              "finding": "Morning dry cough; breathless on two flights of stairs; no hemoptysis"
            },
            {
              "system": "Musculoskeletal",
              "status": "negative",
              "finding": "No bone, back, rib, or hip pain"
            },
            {
              "system": "Neurological",
              "status": "negative",
              "finding": "No headache, weakness, numbness, or unsteadiness"
            },
            {
              "system": "Psychiatric",
              "status": "positive",
              "finding": "Worried; sleeping about five hours; no thoughts of self-harm"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Upright and composed; weight 72.0 kg"
            },
            {
              "system": "Voice",
              "finding": "Breathy, low-volume voice; short phonation time"
            },
            {
              "system": "Lungs",
              "finding": "Slightly reduced breath sounds at the left apex; no wheeze or crackles"
            },
            {
              "system": "Lymph nodes",
              "finding": "No supraclavicular or cervical nodes"
            },
            {
              "system": "Spine and pelvis",
              "finding": "No tenderness over T10, the ribs, or the right iliac crest"
            },
            {
              "system": "Neurological",
              "finding": "Normal strength, sensation, and gait"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-001",
              "display": "Adenocarcinoma of the left upper lobe, stage IVB (cT4 N2 M1c)",
              "assessment": "Tissue diagnosis made: adenocarcinoma, TTF-1 positive, PD-L1 tumor proportion score 70 percent. Staged by PET-CT and brain MRI: mediastinal invasion (T4), aortopulmonary window and subcarinal nodes (N2), and three bone metastases (M1c); no brain metastases. ECOG 1. Plasma testing shows no actionable alteration; tissue sequencing is still pending. The thoracic oncologist recommends first-line pembrolizumab if tissue sequencing confirms no actionable alteration, and not starting an immune checkpoint inhibitor before that result",
              "plan": [
                "Await tissue sequencing, expected within a week; treatment decision at the next visit",
                "Baseline immune-related adverse event laboratory panel before the first infusion",
                "Dental examination on Friday, before a bone-modifying agent",
                "Palliative care visit in two weeks"
              ]
            },
            {
              "problem_id": "PRB-002",
              "display": "Bone metastases, without pain or fracture",
              "assessment": "Three lytic lesions without pain, fracture, or threatened cord; calcium normal",
              "plan": [
                "Zoledronic acid every 12 weeks after the dental examination",
                "Call at once for new back pain, leg weakness, or numbness"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Left vocal fold paralysis",
              "assessment": "Hoarseness from recurrent laryngeal nerve involvement; recovery is unlikely while the tumor is present, but injection medialization can restore much of his voice",
              "plan": [
                "Injection medialization by the ENT surgeon in three weeks",
                "Voice therapy with a speech-language pathologist"
              ]
            },
            {
              "problem_id": "PRB-005",
              "display": "Former smoker",
              "assessment": "No tobacco for 12 years; no cessation treatment needed",
              "plan": [
                "Confirm abstinence at each visit"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "laboratory",
              "measure": "PD-L1 immunohistochemistry (tumor proportion score)",
              "cadence": "At diagnosis; repeat at progression",
              "status": "completed_today",
              "detail": "22C3 assay on the endobronchial ultrasound sample: tumor proportion score 70 percent",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Broad molecular profiling (tissue and plasma)",
              "cadence": "At diagnosis of advanced nonsquamous NSCLC: EGFR, ALK, ROS1, BRAF, KRAS (including G12C), MET exon 14, RET, NTRK, HER2, NRG1, and PD-L1; repeat at progression",
              "status": "ordered",
              "detail": "Plasma cell-free DNA: no actionable alteration. Tissue next-generation sequencing pending; therapy waits for it",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Staging PET-CT and brain MRI",
              "cadence": "At diagnosis of suspected advanced disease",
              "status": "completed_today",
              "detail": "Reviewed today: cT4 N2 M1c (bone), no brain metastases",
              "guideline_ids": [
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Immune-related adverse event laboratory panel",
              "cadence": "Before each immunotherapy infusion: TSH, liver tests, glucose; cortisol at baseline and as indicated",
              "status": "due",
              "detail": "Baseline panel before the first infusion",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ASCO-IRAE-2021"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Response assessment imaging",
              "cadence": "Every 6 to 12 weeks on active systemic therapy",
              "status": "not_indicated",
              "detail": "No systemic therapy started yet",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Dyspnea and cough assessment",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Morning dry cough; breathless on two flights of stairs; no hemoptysis",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Smoking status and cessation support",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Former smoker; no tobacco for 12 years",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Distress and symptom screening (NCCN Distress Thermometer, ESAS)",
              "cadence": "Every visit; at minimum at key transitions",
              "status": "completed_today",
              "detail": "Distress thermometer 6 of 10 (worry, work, voice); ESAS total 18",
              "observation_ids": [
                "OBS-ESAS-V2"
              ],
              "guideline_ids": [
                "GL-NCCN-DISTRESS-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Cancer-related fatigue screening",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Tires by evening; ESAS tiredness 4 of 10",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Depression and anxiety screening",
              "cadence": "At least yearly; more often during active treatment",
              "status": "up_to_date",
              "detail": "PHQ-9 5 two weeks ago; rescreen during treatment",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Weight and dietary review",
              "cadence": "Each follow-up",
              "status": "completed_today",
              "detail": "72.0 kg, stable; eating normally",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Dental evaluation before a bone-modifying agent",
              "cadence": "Baseline, then periodically on zoledronic acid or denosumab",
              "status": "due",
              "detail": "Dental examination booked for Friday",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Chemotherapy-induced peripheral neuropathy",
              "cadence": "Every visit during and after platinum or taxane",
              "status": "not_indicated",
              "detail": "No platinum or taxane planned",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "referral",
              "measure": "Thoracic oncology consultation",
              "cadence": "At diagnosis",
              "status": "completed_today",
              "detail": "Seen today; stage IVB confirmed; pembrolizumab planned if tissue sequencing shows no actionable alteration",
              "guideline_ids": [
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "referral",
              "measure": "Early integrated palliative care",
              "cadence": "Within eight weeks of diagnosis of advanced cancer",
              "status": "referred",
              "detail": "First visit in two weeks",
              "guideline_ids": [
                "GL-ASCO-PALL-2017",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Advance care planning and goals of care",
              "cadence": "At diagnosis and at changes in health",
              "status": "completed_today",
              "detail": "First conversation today: he wants full information and full treatment, and to return to the stage",
              "guideline_ids": [
                "GL-ASCO-PALL-2017",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Voice and work support",
              "cadence": "As needed",
              "status": "referred",
              "detail": "Injection medialization and voice therapy arranged",
              "guideline_ids": [
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Immunizations per ACIP",
              "cadence": "Yearly review",
              "status": "due",
              "detail": "Influenza, pneumococcal, zoster, COVID-19, and RSV to be reviewed at the preventive visit",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Pulmonary rehabilitation",
              "cadence": "Before and after lung resection, or for symptomatic dyspnea or deconditioning",
              "status": "not_indicated",
              "detail": "No resection; not deconditioned",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            }
          ],
          "follow_up": "Dental examination on Friday. Visit next week for the tissue sequencing result and the treatment start. Palliative care in two weeks. Voice injection in three weeks",
          "guideline_ids": [
            "GL-CMID-2026",
            "GL-NCCN-NSCLC-2026",
            "GL-ASCO-IRAE-2021",
            "GL-ASCO-PALL-2017",
            "GL-NCCN-DISTRESS-2026"
          ]
        }
      },
      {
        "id": "ENC-003",
        "display": "Biomarker results and start of first-line pembrolizumab",
        "status": "finished",
        "date": "2026-09-22",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-03"
        },
        "documentation": {
          "chief_complaint": "Tissue sequencing result and start of first-line pembrolizumab",
          "hpi": {
            "narrative": "Mr. Brynner returns one week later. The tissue sequencing report arrived yesterday: KRAS G12V and TP53 mutations, with no EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14, RET, NTRK, HER2, or NRG1 alteration, in agreement with the plasma result. With the thoracic oncologist he chose pembrolizumab alone, given every 3 weeks, rather than with chemotherapy, because it is a preferred first-line option at his PD-L1 level and spares him the fatigue and nausea of chemotherapy while he works toward the stage. His first infusion is this afternoon. The dental examination four days ago found no problems. He is unchanged: weak voice, a little morning cough, no pain, and steady weight. The visit ran long with treatment teaching, and the symptom questionnaire was not completed.",
            "elements": [
              {
                "label": "Tissue sequencing",
                "value": "KRAS G12V and TP53; no actionable alteration"
              },
              {
                "label": "Treatment decision",
                "value": "Pembrolizumab 200 mg every 3 weeks, first dose today"
              },
              {
                "label": "Dental status",
                "value": "Examination four days ago; no work needed"
              },
              {
                "label": "Symptoms",
                "value": "Unchanged; no pain"
              },
              {
                "label": "Tobacco",
                "value": "No tobacco"
              }
            ]
          },
          "ros": [
            {
              "system": "Respiratory",
              "status": "positive",
              "finding": "Morning dry cough; no hemoptysis"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "Bowels regular; no abdominal pain"
            },
            {
              "system": "Endocrine",
              "status": "negative",
              "finding": "No heat or cold intolerance, thirst, or dizziness"
            },
            {
              "system": "Integumentary",
              "status": "negative",
              "finding": "No rash or itching"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well; weight 71.8 kg"
            },
            {
              "system": "Voice",
              "finding": "Breathy, low-volume voice"
            },
            {
              "system": "Lungs",
              "finding": "Slightly reduced breath sounds at the left apex"
            },
            {
              "system": "Skin",
              "finding": "No rash"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-001",
              "display": "Adenocarcinoma of the lung, stage IVB, PD-L1 70 percent, no actionable alteration",
              "assessment": "Biomarker testing complete. With PD-L1 of 50 percent or more and no actionable alteration, pembrolizumab monotherapy is a preferred first-line regimen. Baseline TSH 2.1, free T4 1.2, morning cortisol 14.2, liver tests, glucose, creatinine, calcium, and blood count normal",
              "plan": [
                "Pembrolizumab 200 mg intravenously today, then every 3 weeks",
                "Written list of immune-related warning symptoms and the 24-hour oncology telephone line given",
                "Laboratory panel before each infusion; response CT about nine weeks after starting",
                "Zoledronic acid with the second cycle, so that a first-dose reaction is not confused with an early immune-related event"
              ]
            },
            {
              "problem_id": "PRB-002",
              "display": "Bone metastases",
              "assessment": "No pain; dental examination done",
              "plan": [
                "First zoledronic acid dose with cycle 2"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Left vocal fold paralysis",
              "assessment": "Unchanged",
              "plan": [
                "Injection medialization in two weeks"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "laboratory",
              "measure": "Broad molecular profiling (tissue and plasma)",
              "cadence": "At diagnosis of advanced nonsquamous NSCLC: EGFR, ALK, ROS1, BRAF, KRAS (including G12C), MET exon 14, RET, NTRK, HER2, NRG1, and PD-L1; repeat at progression",
              "status": "completed_today",
              "detail": "Tissue sequencing: KRAS G12V and TP53; no actionable alteration; concordant with plasma",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Immune-related adverse event laboratory panel",
              "cadence": "Before each immunotherapy infusion: TSH, liver tests, glucose; cortisol at baseline and as indicated",
              "status": "completed_today",
              "detail": "Baseline: TSH 2.1, free T4 1.2, morning cortisol 14.2, ALT 26, AST 23, alkaline phosphatase 101, bilirubin 0.6, glucose 94, all normal",
              "observation_ids": [
                "OBS-TSH-V3",
                "OBS-FT4-V3",
                "OBS-CORT-V3",
                "OBS-ALT-V3",
                "OBS-AST-V3",
                "OBS-ALP-V3",
                "OBS-TBIL-V3",
                "OBS-GLU-V3"
              ],
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ASCO-IRAE-2021"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Blood count, kidney function, and calcium before systemic therapy",
              "cadence": "Before each cycle",
              "status": "completed_today",
              "detail": "Hemoglobin 13.6, white cells 7.6, platelets 284, creatinine 0.9 (eGFR 92), calcium 9.5",
              "observation_ids": [
                "OBS-HGB-V3",
                "OBS-WBC-V3",
                "OBS-PLT-V3",
                "OBS-CREAT-V3",
                "OBS-EGFR-V3",
                "OBS-CA-V3"
              ],
              "guideline_ids": [
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Response assessment imaging",
              "cadence": "Every 6 to 12 weeks on active systemic therapy",
              "status": "due",
              "detail": "First response CT about nine weeks after starting",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Dyspnea and cough assessment",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Morning dry cough; unchanged",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Smoking status and cessation support",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Former smoker; no tobacco",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Distress and symptom screening (NCCN Distress Thermometer, ESAS)",
              "cadence": "Every visit; at minimum at key transitions",
              "status": "deferred",
              "detail": "Not done today, at the start of treatment, a key transition: the visit ran long with treatment teaching. Deviation from the every-visit and key-transition screen. No harm resulted: the palliative care team assessed his symptoms and distress in full a week later, and the next scores were lower. Corrective action: the ESAS and distress thermometer are now completed on a tablet at check-in, before the clinician sees him",
              "guideline_ids": [
                "GL-NCCN-DISTRESS-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Cancer-related fatigue screening",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Tired by evening, unchanged; no daytime naps",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Weight and dietary review",
              "cadence": "Each follow-up",
              "status": "completed_today",
              "detail": "71.8 kg, stable",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Dental evaluation before a bone-modifying agent",
              "cadence": "Baseline, then periodically on zoledronic acid or denosumab",
              "status": "completed_today",
              "detail": "Examination four days ago: no active disease, no extractions needed",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "referral",
              "measure": "Early integrated palliative care",
              "cadence": "Within eight weeks of diagnosis of advanced cancer",
              "status": "referred",
              "detail": "First visit next week",
              "guideline_ids": [
                "GL-ASCO-PALL-2017",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Voice and work support",
              "cadence": "As needed",
              "status": "referred",
              "detail": "Injection medialization in two weeks; voice therapy started",
              "guideline_ids": [
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Chemotherapy-induced peripheral neuropathy",
              "cadence": "Every visit during and after platinum or taxane",
              "status": "not_indicated",
              "detail": "Pembrolizumab alone; no platinum or taxane",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            }
          ],
          "follow_up": "First pembrolizumab infusion this afternoon. Palliative care next week. Voice injection in two weeks. Cycle 2 in three weeks with the laboratory panel and the first zoledronic acid dose. Call the oncology line for any warning symptom",
          "guideline_ids": [
            "GL-CMID-2026",
            "GL-NCCN-NSCLC-2026",
            "GL-ASCO-IRAE-2021",
            "GL-ASCO-PALL-2017",
            "GL-NCCN-DISTRESS-2026"
          ]
        }
      },
      {
        "id": "ENC-004",
        "display": "Cycle 2 review: immune-related adverse event monitoring, symptoms, and return to work",
        "status": "finished",
        "date": "2026-10-13",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-03"
        },
        "documentation": {
          "chief_complaint": "Cycle 2 review on pembrolizumab",
          "hpi": {
            "narrative": "Mr. Brynner returns three weeks after his first pembrolizumab infusion, for cycle 2. He felt a little more tired for two days after the infusion and has otherwise felt well. He has had no diarrhea, abdominal pain, new cough or breathlessness, rash or itching, headache, dizziness, thirst, or yellowing. He saw the palliative care team two weeks ago and found the conversation about his goals and his worries useful; he is sleeping better. The injection medialization of his left vocal fold a week ago made his voice louder and less breathy, and he has begun light rehearsal with the voice therapist's exercises. He wants to rejoin the tour for a few performances a week next month. He has had no bone pain and has not smoked. His first zoledronic acid dose is today, with the pembrolizumab.",
            "elements": [
              {
                "label": "Tolerance of cycle 1",
                "value": "Two days of extra tiredness; no immune-related symptoms"
              },
              {
                "label": "Palliative care",
                "value": "First visit two weeks ago"
              },
              {
                "label": "Voice",
                "value": "Louder after injection medialization a week ago; light rehearsal begun"
              },
              {
                "label": "Work",
                "value": "Plans a graded return to the tour next month"
              },
              {
                "label": "Bone symptoms",
                "value": "None"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "positive",
              "finding": "Two days of extra tiredness after the infusion; no fever"
            },
            {
              "system": "Respiratory",
              "status": "positive",
              "finding": "Occasional morning dry cough, unchanged; no new breathlessness"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "No diarrhea, abdominal pain, or blood in the stool"
            },
            {
              "system": "Integumentary",
              "status": "negative",
              "finding": "No rash or itching"
            },
            {
              "system": "Endocrine",
              "status": "negative",
              "finding": "No headache, dizziness, heat or cold intolerance, or thirst"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "Mood steady; sleeping better; no thoughts of self-harm"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well; weight 72.2 kg"
            },
            {
              "system": "Voice",
              "finding": "Louder and less breathy; longer phonation time"
            },
            {
              "system": "Lungs",
              "finding": "Slightly reduced breath sounds at the left apex; no crackles"
            },
            {
              "system": "Skin",
              "finding": "No rash"
            },
            {
              "system": "Mouth",
              "finding": "Good dentition; no exposed bone"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-001",
              "display": "Adenocarcinoma of the lung, stage IVB, on pembrolizumab",
              "assessment": "Cycle 1 tolerated well. TSH 2.4 and free T4 1.1, liver tests, creatinine, and blood count normal; glucose 104 mg/dL on a mid-morning, non-fasting sample is not a concern. No immune-related adverse event. ESAS 12, down from 18; PHQ-9 4",
              "plan": [
                "Pembrolizumab cycle 2 today",
                "Laboratory panel before cycle 3; response CT about nine weeks after starting",
                "Once the first response scan is reviewed, consider pembrolizumab 400 mg every 6 weeks to fit the tour"
              ]
            },
            {
              "problem_id": "PRB-002",
              "display": "Bone metastases",
              "assessment": "No pain; calcium 9.4 and eGFR 92; dental examination done",
              "plan": [
                "Zoledronic acid 4 mg today, then every 12 weeks",
                "Vitamin D3 1000 units daily and calcium from food",
                "Acetaminophen for aches after the first dose if needed"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Left vocal fold paralysis, after injection medialization",
              "assessment": "Voice much improved",
              "plan": [
                "Continue voice therapy; graded return to performing as he chooses, with rest days between performances at first"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "laboratory",
              "measure": "Immune-related adverse event laboratory panel",
              "cadence": "Before each immunotherapy infusion: TSH, liver tests, glucose; cortisol at baseline and as indicated",
              "status": "completed_today",
              "detail": "TSH 2.4, free T4 1.1, ALT 30, AST 27, bilirubin 0.7, glucose 104 (non-fasting); no immune-related adverse event",
              "observation_ids": [
                "OBS-TSH-V4",
                "OBS-FT4-V4",
                "OBS-ALT-V4",
                "OBS-AST-V4",
                "OBS-TBIL-V4",
                "OBS-GLU-V4"
              ],
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ASCO-IRAE-2021"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Morning cortisol",
              "cadence": "At baseline and as indicated by symptoms (ASCO); the CMID lists it before each infusion",
              "status": "not_indicated",
              "detail": "Baseline 14.2 was normal, and he has no fatigue, dizziness, low blood pressure, or low sodium suggesting adrenal or pituitary injury; repeated if symptoms appear",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-ASCO-IRAE-2021"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Blood count, kidney function, and calcium before treatment and before zoledronic acid",
              "cadence": "Before each cycle and each zoledronic acid dose",
              "status": "completed_today",
              "detail": "Hemoglobin 13.5, white cells 7.2, platelets 270, creatinine 0.9 (eGFR 92), calcium 9.4",
              "observation_ids": [
                "OBS-HGB-V4",
                "OBS-WBC-V4",
                "OBS-PLT-V4",
                "OBS-CREAT-V4",
                "OBS-EGFR-V4",
                "OBS-CA-V4"
              ],
              "guideline_ids": [
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Response assessment imaging",
              "cadence": "Every 6 to 12 weeks on active systemic therapy",
              "status": "due",
              "detail": "First response CT in about six weeks, nine weeks after starting",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Dyspnea and cough assessment",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Occasional morning cough, unchanged; no new breathlessness to suggest pneumonitis",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Smoking status and cessation support",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Former smoker; no tobacco",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Distress and symptom screening (NCCN Distress Thermometer, ESAS)",
              "cadence": "Every visit; at minimum at key transitions",
              "status": "completed_today",
              "detail": "ESAS total 12, down from 18; distress thermometer 3 of 10; completed at check-in",
              "observation_ids": [
                "OBS-ESAS-V4"
              ],
              "guideline_ids": [
                "GL-NCCN-DISTRESS-2026",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Depression and anxiety screening",
              "cadence": "At least yearly; more often during active treatment",
              "status": "completed_today",
              "detail": "PHQ-9 4, item 9 scored 0",
              "observation_ids": [
                "OBS-PHQ9-V4"
              ],
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Cancer-related fatigue screening",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Two days of extra tiredness after cycle 1, then back to his usual",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Weight and dietary review",
              "cadence": "Each follow-up",
              "status": "completed_today",
              "detail": "72.2 kg, stable",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Dental evaluation on a bone-modifying agent",
              "cadence": "Baseline, then periodically on zoledronic acid or denosumab",
              "status": "up_to_date",
              "detail": "Baseline examination three weeks ago; routine dental care every six months",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "referral",
              "measure": "Early integrated palliative care",
              "cadence": "Within eight weeks of diagnosis of advanced cancer",
              "status": "completed_today",
              "detail": "First visit two weeks ago, two weeks after diagnosis; follow-up next month",
              "guideline_ids": [
                "GL-ASCO-PALL-2017",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Voice and work support",
              "cadence": "As needed",
              "status": "completed_today",
              "detail": "Injection medialization a week ago; voice therapy continues; graded return to the tour planned",
              "guideline_ids": [
                "GL-NCCN-NSCLC-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Immunizations per ACIP",
              "cadence": "Yearly review",
              "status": "due",
              "detail": "Influenza, PCV20, and zoster at the preventive visit in two weeks",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Chemotherapy-induced peripheral neuropathy",
              "cadence": "Every visit during and after platinum or taxane",
              "status": "not_indicated",
              "detail": "No platinum or taxane",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NCCN-NSCLC-2026"
              ]
            }
          ],
          "follow_up": "Pembrolizumab cycle 2 and zoledronic acid today. Preventive visit in two weeks. Cycle 3 in three weeks with the laboratory panel. Response CT about nine weeks after starting",
          "guideline_ids": [
            "GL-CMID-2026",
            "GL-NCCN-NSCLC-2026",
            "GL-ASCO-IRAE-2021",
            "GL-ASCO-PALL-2017",
            "GL-NCCN-DISTRESS-2026"
          ]
        }
      },
      {
        "id": "ENC-005",
        "display": "Same-day sick visit for an itchy rash on pembrolizumab",
        "status": "finished",
        "date": "2026-10-20",
        "visit_type": "sick",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "185345009",
          "display": "Encounter for symptom",
          "validation_status": "validated",
          "validated_on": "2026-11-03"
        },
        "documentation": {
          "chief_complaint": "Itchy rash on the chest, back, and arms for four days, during pembrolizumab treatment",
          "billing_note": "Problem-oriented office visit, established patient",
          "hpi": {
            "narrative": "Mr. Brynner is a 63-year-old man with stage IVB adenocarcinoma of the left upper lobe (PD-L1 70 percent, no actionable alteration) who had his second pembrolizumab infusion one week ago and his first zoledronic acid dose the same day. He asked for a same-day visit for an itchy rash. Four days ago he noticed small red bumps on his chest that have spread to his upper back and the inner arms. The itching is worst at night and in the heat of the stage lights at rehearsal, but he is sleeping. He has had no blisters, peeling, mouth or eye soreness, genital sores, or fever. The aches he had for a day after the zoledronic acid dose have gone. He has started no new soap, detergent, or medicine other than the infusions. He has had no diarrhea, abdominal pain, cough, breathlessness, headache, unusual fatigue, or yellowing of the skin or eyes. His voice remains improved since the injection two weeks ago.",
            "elements": [
              {
                "label": "Onset",
                "value": "Four days ago, three and a half weeks after the first pembrolizumab dose and three days after the second"
              },
              {
                "label": "Location",
                "value": "Chest, upper back, and inner arms; face, palms, soles, and mucous membranes spared"
              },
              {
                "label": "Duration",
                "value": "Four days, slowly spreading"
              },
              {
                "label": "Character",
                "value": "Small red raised spots that join in places; itchy"
              },
              {
                "label": "Severity",
                "value": "Mild; about 8 percent of body surface area; sleeping and working"
              },
              {
                "label": "Timing",
                "value": "Itching worst at night and under hot stage lights"
              },
              {
                "label": "Context",
                "value": "On pembrolizumab every 3 weeks; first zoledronic acid dose one week ago; no new exposures"
              },
              {
                "label": "Modifying factors",
                "value": "Cool showers help; nothing taken"
              },
              {
                "label": "Associated signs and symptoms",
                "value": "Denies fever, blisters, mucosal sores, diarrhea, cough, breathlessness, headache, and jaundice"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "No fever, chills, or unusual fatigue"
            },
            {
              "system": "Integumentary",
              "status": "positive",
              "finding": "Itchy red rash on the trunk and arms; no blisters or peeling"
            },
            {
              "system": "Eyes",
              "status": "negative",
              "finding": "No redness, pain, or change in vision"
            },
            {
              "system": "Ears, nose, mouth, and throat",
              "status": "negative",
              "finding": "No mouth sores; voice improved"
            },
            {
              "system": "Respiratory",
              "status": "negative",
              "finding": "No new cough or breathlessness"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "No diarrhea, abdominal pain, or dark urine"
            },
            {
              "system": "Endocrine",
              "status": "negative",
              "finding": "No headache, dizziness, heat or cold intolerance, or excessive thirst"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well and comfortable; afebrile at 36.7 °C"
            },
            {
              "system": "Skin",
              "finding": "Discrete and partly joined pink macules and papules over the anterior chest, upper back, and inner upper arms, about 8 percent of body surface area; scratch marks; no blisters, target lesions, skin pain, or peeling; Nikolsky sign negative"
            },
            {
              "system": "Mucous membranes",
              "finding": "Mouth, lips, and eyes normal"
            },
            {
              "system": "Lymph nodes",
              "finding": "No new enlargement"
            },
            {
              "system": "Lungs",
              "finding": "Clear; oxygen saturation 97 percent"
            },
            {
              "system": "Abdomen",
              "finding": "Soft and non-tender; no liver enlargement"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-006",
              "display": "Immune-related maculopapular rash, grade 1",
              "assessment": "Itchy maculopapular rash over less than 10 percent of the body surface, starting three and a half weeks into pembrolizumab, without blisters, mucosal involvement, skin pain, or fever: grade 1 immune-related dermatitis. No feature of a severe cutaneous reaction. TSH 2.6, free T4 1.1, and liver tests and creatinine normal, so no second immune-related event; eosinophils mildly raised at 0.62, typical of a drug-related rash. Zoledronic acid is an unlikely cause. Pembrolizumab can continue",
              "plan": [
                "Triamcinolone 0.1% cream twice daily for up to two weeks, not on the face or skin folds",
                "Cetirizine 10 mg daily as needed for itching; fragrance-free emollient twice daily; cool showers",
                "Continue pembrolizumab on schedule; oncology informed today and agrees",
                "Return the same day for blisters, skin pain or peeling, mouth or eye sores, fever, or spread to more than a tenth of the body; photograph the rash every two days"
              ]
            },
            {
              "problem_id": "PRB-001",
              "display": "Stage IVB adenocarcinoma of the lung on pembrolizumab",
              "assessment": "Second cycle given one week ago; no other immune-related symptoms",
              "plan": [
                "Cycle 3 in two weeks after the laboratory panel",
                "Response CT about nine weeks after starting, as planned"
              ]
            }
          ],
          "follow_up": "Skin check at the preventive visit next week, or sooner as above. Cycle 3 in two weeks",
          "guideline_ids": [
            "GL-ASCO-IRAE-2021",
            "GL-NCCN-NSCLC-2026",
            "GL-CMID-2026"
          ]
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic unscheduled sick visit for a common immune-related adverse event; not a claim about his real illness.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "ENC-006",
        "display": "Periodic adult preventive visit",
        "status": "finished",
        "date": "2026-10-27",
        "visit_type": "preventive_adult",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "86013001",
          "display": "Periodic reevaluation and management of healthy individual",
          "validation_status": "validated",
          "validated_on": "2026-11-03"
        },
        "documentation": {
          "chief_complaint": "Adult preventive visit; rash improving",
          "billing_note": "CPT 99396 (periodic preventive medicine visit, established patient, 40 to 64 years) with CPT 99497 (advance care planning), on the same day",
          "hpi": {
            "narrative": "Mr. Brynner is a 63-year-old man with stage IVB adenocarcinoma of the left upper lobe on first-line pembrolizumab every 3 weeks (two cycles so far) and zoledronic acid every 12 weeks, who comes for his yearly preventive visit, timed before the respiratory virus season. The rash seen last week is fading with the triamcinolone cream, and the itching is much less; he has used cetirizine on three nights. He has had no new symptoms of immune-related side effects. His voice is stronger after the injection medialization and voice therapy, and he has begun rehearsing two hours a day; he hopes to rejoin the tour for a few performances a week next month. He saw the palliative care team four weeks ago and found it useful. He completed the health risk assessment before the visit.",
            "elements": [
              {
                "label": "Visit",
                "value": "Adult preventive visit"
              },
              {
                "label": "Active treatment",
                "value": "Pembrolizumab every 3 weeks; zoledronic acid every 12 weeks; vitamin D3 daily"
              },
              {
                "label": "Interval change",
                "value": "Rash fading on topical steroid; no other immune-related symptoms"
              },
              {
                "label": "Work",
                "value": "Rehearsing two hours a day; plans a graded return to the tour"
              },
              {
                "label": "Supports",
                "value": "Spouse, company manager, and the palliative care team"
              }
            ]
          },
          "health_risk_assessment": [
            {
              "domain": "Self-rated health",
              "finding": "Good, apart from tiring by evening"
            },
            {
              "domain": "Psychosocial",
              "finding": "Worried about the future but coping; strong sense of purpose in returning to the stage; supportive spouse and company"
            },
            {
              "domain": "Tobacco",
              "finding": "Former smoker; no tobacco for 12 years"
            },
            {
              "domain": "Alcohol and drugs",
              "finding": "A glass of wine two or three nights a week (AUDIT-C 2); no other drug use"
            },
            {
              "domain": "Physical activity",
              "finding": "Walks 30 minutes most days and does stage warm-ups"
            },
            {
              "domain": "Nutrition",
              "finding": "Eating well; weight stable at about 72 kg"
            },
            {
              "domain": "Sleep",
              "finding": "About seven hours a night; itching woke him twice last week"
            },
            {
              "domain": "Activities of daily living",
              "finding": "Independent"
            },
            {
              "domain": "Instrumental activities of daily living",
              "finding": "Independent; company manager handles travel bookings"
            },
            {
              "domain": "Home and travel safety",
              "finding": "Smoke detectors at home; seat belt always; hotel rooms booked near elevators"
            },
            {
              "domain": "Falls",
              "finding": "None"
            },
            {
              "domain": "Hearing and vision",
              "finding": "Reading glasses; no hearing difficulty"
            }
          ],
          "ros": [
            {
              "system": "Constitutional",
              "status": "positive",
              "finding": "Tires by evening; no fever, night sweats, or weight loss since starting treatment"
            },
            {
              "system": "Eyes",
              "status": "negative",
              "finding": "No redness or change in vision"
            },
            {
              "system": "Ears, nose, mouth, and throat",
              "status": "positive",
              "finding": "Voice still slightly breathy after a long rehearsal; no mouth sores"
            },
            {
              "system": "Cardiovascular",
              "status": "negative",
              "finding": "No chest pain, palpitations, or ankle swelling"
            },
            {
              "system": "Respiratory",
              "status": "positive",
              "finding": "Occasional dry cough in the morning; mild breathlessness on two flights of stairs, unchanged"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "No diarrhea, abdominal pain, or blood in the stool"
            },
            {
              "system": "Genitourinary",
              "status": "negative",
              "finding": "No urinary symptoms"
            },
            {
              "system": "Musculoskeletal",
              "status": "negative",
              "finding": "No back, hip, or rib pain"
            },
            {
              "system": "Integumentary",
              "status": "positive",
              "finding": "Rash fading; mild itch"
            },
            {
              "system": "Neurological",
              "status": "negative",
              "finding": "No headache, weakness, or numbness"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "Mood steady; PHQ-2 score 1"
            },
            {
              "system": "Endocrine",
              "status": "negative",
              "finding": "No heat or cold intolerance or excessive thirst"
            }
          ],
          "exam": [
            {
              "system": "Constitutional",
              "finding": "Well, upright, and commanding; weight 72.3 kg, BMI 22.8"
            },
            {
              "system": "Eyes",
              "finding": "Pupils equal and reactive; conjunctivae normal"
            },
            {
              "system": "Ears, nose, and throat",
              "finding": "Voice louder and less breathy than at presentation; oral mucosa normal; good dentition"
            },
            {
              "system": "Neck",
              "finding": "No supraclavicular or cervical nodes; thyroid not enlarged"
            },
            {
              "system": "Cardiovascular",
              "finding": "Regular rhythm at 74 per minute; no murmur; no edema"
            },
            {
              "system": "Respiratory",
              "finding": "Slightly reduced breath sounds at the left apex; no wheeze or crackles"
            },
            {
              "system": "Abdomen",
              "finding": "Soft and non-tender; no liver enlargement"
            },
            {
              "system": "Musculoskeletal",
              "finding": "No spinal, pelvic, or rib tenderness"
            },
            {
              "system": "Skin",
              "finding": "Fading pink macules on the chest and back; no new lesions; no suspicious moles"
            },
            {
              "system": "Neurological",
              "finding": "Alert and oriented; normal strength and gait"
            },
            {
              "system": "Psychiatric",
              "finding": "Composed and engaged; good insight"
            }
          ],
          "assessment_plan": [
            {
              "display": "Adult preventive visit completed",
              "assessment": "Health risk assessment reviewed and a written prevention plan given, adapted to active treatment for metastatic lung cancer: vaccines are the priority, and screening tests whose benefit takes years are deferred until the first response scan. Depression and alcohol screens negative",
              "plan": [
                "Influenza, PCV20, and recombinant zoster dose 1 today",
                "COVID-19 vaccine next week; RSV vaccine at the next visit",
                "Next preventive visit in one year"
              ]
            },
            {
              "problem_id": "PRB-006",
              "display": "Immune-related rash, grade 1, improving",
              "assessment": "Fading with topical steroid; no blisters or mucosal involvement",
              "plan": [
                "Finish the two-week course of triamcinolone, then emollient alone",
                "Cetirizine as needed"
              ]
            },
            {
              "problem_id": "PRB-001",
              "display": "Stage IVB adenocarcinoma of the lung on pembrolizumab",
              "assessment": "Two cycles given; no other immune-related events; preparing to return to work",
              "plan": [
                "Cycle 3 next week after the laboratory panel",
                "Response CT in about four weeks",
                "Palliative care follow-up next month"
              ]
            }
          ],
          "prevention_plan": [
            {
              "service": "Influenza vaccine, this season",
              "status": "completed_today",
              "detail": "Inactivated vaccine given today; safe on checkpoint inhibitor therapy",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Pneumococcal vaccine",
              "status": "completed_today",
              "detail": "PCV20 given today; recommended once for all adults 50 and older",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Recombinant zoster vaccine",
              "status": "completed_today",
              "detail": "Dose 1 given today; dose 2 in two to six months",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "COVID-19 vaccine, this season",
              "status": "due",
              "detail": "Recommended; at his pharmacy next week, spaced from today's vaccines at his request",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "RSV vaccine",
              "status": "due",
              "detail": "Recommended at 60 to 74 for adults at increased risk, which his lung cancer confers; planned for the next visit",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Tetanus, diphtheria, and pertussis booster",
              "status": "up_to_date",
              "detail": "Tdap six years ago",
              "guideline_ids": [
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "service": "Colorectal cancer screening",
              "status": "due",
              "detail": "Recommended at 45 to 75; deferred by shared decision while he starts treatment for metastatic cancer; to be revisited after the first response scan",
              "guideline_ids": [
                "GL-USPSTF-CRC-2021"
              ]
            },
            {
              "service": "Prostate cancer screening",
              "status": "declined",
              "detail": "Individual decision at 55 to 69; after discussion he declined PSA testing while on cancer treatment",
              "guideline_ids": [
                "GL-USPSTF-PROSTATE-2018"
              ]
            },
            {
              "service": "Lung cancer screening",
              "status": "not_indicated",
              "detail": "He has lung cancer and is followed with response imaging",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "service": "Abdominal aortic aneurysm screening",
              "status": "not_indicated",
              "detail": "One-time ultrasound for men 65 to 75 who have ever smoked; he is 63, and his staging CT showed a normal abdominal aorta",
              "guideline_ids": [
                "GL-USPSTF-AAA-2019"
              ]
            },
            {
              "service": "Hepatitis C and HIV screening",
              "status": "up_to_date",
              "detail": "One-time screening for both done in the past, negative",
              "guideline_ids": [
                "GL-USPSTF-AB"
              ]
            },
            {
              "service": "Cholesterol screening and statin decision",
              "status": "due",
              "detail": "Deferred by shared decision while he starts treatment for metastatic cancer",
              "guideline_ids": [
                "GL-USPSTF-AB"
              ]
            },
            {
              "service": "Diabetes screening",
              "status": "up_to_date",
              "detail": "Glucose is checked before each pembrolizumab infusion; 94 to 104 mg/dL",
              "guideline_ids": [
                "GL-USPSTF-AB"
              ]
            },
            {
              "service": "Blood pressure screening",
              "status": "completed_today",
              "detail": "124/76 mmHg",
              "guideline_ids": [
                "GL-USPSTF-AB"
              ]
            },
            {
              "service": "Depression screening",
              "status": "completed_today",
              "detail": "PHQ-2 score 1; PHQ-9 4 two weeks ago",
              "guideline_ids": [
                "GL-USPSTF-DEP-2023"
              ]
            },
            {
              "service": "Unhealthy alcohol use screening",
              "status": "completed_today",
              "detail": "AUDIT-C 2, below the risk threshold",
              "guideline_ids": [
                "GL-USPSTF-AB"
              ]
            },
            {
              "service": "Tobacco use",
              "status": "completed_today",
              "detail": "Former smoker; no tobacco for 12 years",
              "guideline_ids": [
                "GL-USPSTF-AB"
              ]
            },
            {
              "service": "Skin examination",
              "status": "completed_today",
              "detail": "Rash fading; no suspicious lesions"
            }
          ],
          "advance_care_planning": "Voluntary advance care planning discussion of about 30 minutes, with his consent, building on the goals-of-care conversation with the palliative care team. We talked about what metastatic lung cancer can mean, that treatment aims to control it and help him live well for as long as possible rather than to cure it, and why it helps to plan ahead while he is well. He named a health care agent, who is recorded in the chart and not named here, and took a health care proxy form and a living will form home. He said what matters most to him is to keep working on the stage for as long as he can and to be told the truth plainly. He wants full cancer treatment now. He chose not to record other specific treatment preferences today. The plan will be revisited at the first response scan and at any change in his health.",
          "follow_up": "Cycle 3 of pembrolizumab next week. COVID-19 vaccine at the pharmacy next week. Response CT in about four weeks. RSV vaccine and zoster dose 2 at later visits. Next preventive visit in one year",
          "guideline_ids": [
            "GL-PREV-2026",
            "GL-USPSTF-AB",
            "GL-CDC-IMZ-2026",
            "GL-CMID-2026",
            "GL-ASCO-PALL-2017"
          ]
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic adult preventive visit (USPSTF services); not a Medicare wellness visit, because he is under 65.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      }
    ],
    "vital_sign_sets": [
      {
        "id": "VSET-001",
        "date": "2026-09-01",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 178,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 72.4,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 22.9,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 132,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 80,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 82,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.8,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 96,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vital signs; no measurement from his lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "VSET-002",
        "date": "2026-09-15",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 178,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 72.0,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 22.7,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 128,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 78,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 80,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.7,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 96,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vital signs; no measurement from his lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "VSET-003",
        "date": "2026-09-22",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 178,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 71.8,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 22.7,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 126,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 78,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 78,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 96,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vital signs; no measurement from his lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "VSET-004",
        "date": "2026-10-13",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 178,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 72.2,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 22.8,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 124,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 76,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 76,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.7,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vital signs; no measurement from his lifetime is used.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "VSET-005",
        "date": "2026-10-20",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 178,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 72.0,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 22.7,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 126,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 78,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 78,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.7,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vital signs at the sick visit; afebrile.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "VSET-006",
        "date": "2026-10-27",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 178,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 72.3,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 22.8,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 124,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 76,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 74,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 97,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vital signs at the preventive visit.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      }
    ],
    "social_history": [
      {
        "id": "SOC-001",
        "display": "Former smoker: about 3 packs a day from age 12 until he quit 12 years ago (roughly 115 pack-years); no tobacco, vaping, or cannabis since; wants other smokers to hear his story",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004",
            "CLM-0007"
          ],
          "synthetic_reason": "Synthetic modern entry anchored to the documented heavy smoking and quitting.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "SOC-002",
        "display": "Alcohol: a glass of wine with dinner two or three nights a week (AUDIT-C 2); no other drug use",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic alcohol history; not a claim about his real drinking.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "SOC-003",
        "display": "Stage actor and singer, leading a national touring production with eight performances a week; has paused the tour for the tests and wants to return as soon as he safely can",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0003",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic modern occupation echoing his documented career.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "SOC-004",
        "display": "Married; lives in an apartment in New York and on the road during the tour; a company manager and a long-time dresser help with the travel schedule",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic living situation; family members are unnamed and give no statements or health information.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "SOC-005",
        "display": "No occupational asbestos, radon, or diesel exposure known; no family history of lung cancer known to him",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic exposure review.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      }
    ],
    "functional_status": [
      {
        "id": "FUNC-001",
        "display": "ECOG performance status 1: fully active offstage, but tires by the end of an evening and has stopped singing because of the weak voice; walks briskly without breathlessness on the level; climbs two flights with mild breathlessness",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic functional status.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      }
    ],
    "mental_status": [
      {
        "id": "MSE-001",
        "display": "Alert, commanding, and precise; wants the facts plainly and in full",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic mental-status finding.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "MSE-002",
        "display": "Worried but composed; PHQ-9 score 5 with item 9 scored 0; no thoughts of suicide or self-harm",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic mental-status finding.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      }
    ],
    "consultation": {
      "referral": {
        "question": "Left upper lobe mass invading the mediastinum with mediastinal nodes and left vocal fold paralysis in a 63-year-old former heavy smoker. Please establish the diagnosis and stage, direct biomarker testing, and advise on first-line treatment",
        "urgency": "Urgent, within two weeks",
        "pertinent_history": "Six weeks of a weak, breathy voice; he is a stage actor and singer and has paused his tour. Laryngoscopy today: left vocal fold immobile, no laryngeal mass. CT of the chest, abdomen, and pelvis today: 5.2 cm left upper lobe mass invading the aortopulmonary window fat and abutting the aortic arch and left pulmonary artery, enlarged aortopulmonary window and subcarinal nodes, and a small lytic lesion in T10; no adrenal or liver lesion. Mild morning cough, no hemoptysis, no pain, about 2 kg weight loss. ECOG 1. Former smoker: about 3 packs a day from age 12 until he quit 12 years ago (roughly 115 pack-years). Blood count, sodium, potassium, creatinine (eGFR 92), calcium 9.6, liver tests, and glucose normal. PHQ-9 5. PET-CT and brain MRI ordered for this week, and endobronchial ultrasound biopsy requested. He wants plain facts and to return to performing",
        "questions": [
          "What is the diagnosis and stage once the PET-CT, brain MRI, and biopsy are done, and is the lytic T10 lesion a metastasis?",
          "Is the biomarker testing complete enough to choose treatment (PD-L1 and comprehensive genomic profiling, tissue and plasma), and should treatment wait for it?",
          "What first-line systemic therapy do you recommend?",
          "Is there a role now for surgery, radiation, or a bone-modifying agent?",
          "What immune-related adverse event monitoring should primary care carry out, and what should prompt a call?",
          "How should palliative care, symptom management, and his wish to keep performing be built into the plan?"
        ]
      },
      "consultant_note": {
        "history": "Mr. Brynner is seen at the request of Dr. Achterberg two weeks after he presented with six weeks of a weak, breathy voice. He is a stage actor and singer leading a touring production, which he has paused. He smoked about three packs a day from the age of 12 and quit 12 years ago. He has a mild morning cough, no hemoptysis, no chest, bone, or back pain, no headache, and no neurological symptoms, and his weight is steady after a small loss before presentation. He is fully active offstage but tires by evening. He has no autoimmune disease, organ transplant, or use of corticosteroids or other immunosuppressants. He wants the facts in full and wants to return to the stage",
        "data_reviewed": "Laryngoscopy; CT of the chest, abdomen, and pelvis; FDG PET-CT and brain MRI eleven days ago; endobronchial ultrasound needle aspiration six days ago with cytology, immunohistochemistry, and PD-L1; plasma cell-free DNA sequencing; intake laboratory results",
        "exam": [
          {
            "system": "General",
            "finding": "Upright and composed; ECOG 1; weight 72.0 kg"
          },
          {
            "system": "Voice",
            "finding": "Breathy, low-volume voice"
          },
          {
            "system": "Lymph nodes",
            "finding": "No supraclavicular or cervical nodes"
          },
          {
            "system": "Lungs",
            "finding": "Slightly reduced breath sounds at the left apex"
          },
          {
            "system": "Spine and pelvis",
            "finding": "No tenderness over T10, the ribs, or the right iliac crest"
          },
          {
            "system": "Neurological",
            "finding": "Normal strength, sensation, and gait"
          }
        ],
        "assessment": [
          {
            "problem_id": "PRB-001",
            "display": "Adenocarcinoma of the left upper lobe, stage IVB (cT4 N2 M1c)",
            "assessment": "Adenocarcinoma, TTF-1 and napsin A positive, from subcarinal and 4L nodes. The primary invades the mediastinum (T4), the aortopulmonary window and subcarinal nodes are involved (N2), and PET-CT shows avid lytic lesions at T10, the right ilium, and the left sixth rib (M1c, stage IVB). Several typical avid lytic lesions do not need biopsy, because confirming one would not change treatment. The brain MRI is clear. The tumor is not resectable and not curable with surgery or chemoradiation; treatment aims at control, symptom relief, and time"
          },
          {
            "display": "Biomarkers",
            "assessment": "PD-L1 (22C3) tumor proportion score 70 percent. Plasma testing shows no actionable alteration, but a negative plasma result does not exclude a driver, so tissue sequencing (EGFR, ALK, ROS1, BRAF, KRAS G12C, MET exon 14, RET, NTRK, HER2, NRG1) must be reviewed before an immune checkpoint inhibitor is started: starting one before a targetable driver is found can raise the toxicity of later targeted therapy and gives less benefit. The result is expected within a week, so waiting costs little"
          },
          {
            "display": "First-line therapy",
            "assessment": "If no actionable alteration is found, NCCN lists pembrolizumab alone, or pembrolizumab with carboplatin and pemetrexed, among the preferred first-line options for PD-L1 50 percent or more. With ECOG 1, no visceral crisis, and his wish to keep his energy and voice for the stage, pembrolizumab 200 mg every 3 weeks is recommended, with chemotherapy added at progression. He has no autoimmune or transplant history that would argue against immunotherapy. After the first response scan, 400 mg every 6 weeks would fit touring"
          },
          {
            "problem_id": "PRB-002",
            "display": "Bone metastases",
            "assessment": "No pain, fracture, or threatened cord, so no radiation is needed now. A bone-modifying agent reduces skeletal events: zoledronic acid 4 mg every 12 weeks after a dental examination, with calcium and vitamin D. Palliative radiation if a lesion becomes painful or threatens fracture"
          },
          {
            "problem_id": "PRB-003",
            "display": "Left vocal fold paralysis",
            "assessment": "Caused by recurrent laryngeal nerve involvement in the aortopulmonary window. Radiation is unlikely to restore nerve function; injection medialization and voice therapy offer the best chance of a stage-worthy voice"
          }
        ],
        "recommendations": [
          "Wait for tissue sequencing, expected within a week; if it shows no actionable alteration, start pembrolizumab 200 mg every 3 weeks",
          "Baseline TSH, free T4, morning cortisol, liver tests, glucose, creatinine, and blood count; then TSH, free T4, liver tests, glucose, creatinine, and blood count before each infusion, with cortisol for fatigue, dizziness, low blood pressure, or low sodium",
          "Give him a written list of warning symptoms (diarrhea, new cough or breathlessness, rash, yellowing, severe fatigue, headache, or dizziness) and the 24-hour oncology telephone line; primary care should call oncology the same day for any of them and should not start corticosteroids without discussion, except in an emergency",
          "Response CT of the chest, abdomen, and pelvis about nine weeks after starting, then every 6 to 12 weeks",
          "Dental examination, then zoledronic acid 4 mg every 12 weeks with calcium and vitamin D; start it with the second cycle so that a first-dose reaction is not confused with an early immune-related event",
          "Early palliative care within the next few weeks, alongside treatment, with symptom and distress screening at every visit",
          "Injection medialization and voice therapy, and a graded return to performing as he chooses, with infusions scheduled around his work",
          "No surgery and no radiation now"
        ],
        "communication": "Discussed with Dr. Achterberg the same day; the patient agrees and asked that treatment fit his return to the stage",
        "follow_up": "Thoracic oncology will see him next week with the tissue sequencing result to start treatment, and at each cycle. Primary care will continue the CMID lung cancer monitoring, preventive care, and coordination with palliative care"
      },
      "guideline_ids": [
        "GL-NCCN-NSCLC-2026",
        "GL-CMID-2026",
        "GL-ASCO-IRAE-2021",
        "GL-ASCO-PALL-2017",
        "GL-NCCN-DISTRESS-2026"
      ]
    }
  },
  "care_plan": {
    "health_concerns": [
      {
        "id": "HC-001",
        "display": "His voice has become weak and breathy, and he cannot sing or project on stage",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic patient-centered concern anchored to the published account of a vocal-cord problem.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "HC-002",
        "display": "He wants to get back to performing and to keep working for as long as he can",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic patient-centered concern anchored to his documented return to the stage.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "HC-003",
        "display": "He wants people to know what smoking did to him",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0007",
            "CLM-0008"
          ],
          "synthetic_reason": "Synthetic patient-centered concern anchored to his public statements about smoking.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      }
    ],
    "goals": [
      {
        "id": "GOAL-001",
        "display": "Tissue diagnosis, full staging, PD-L1, and comprehensive biomarker results before any systemic therapy, within three weeks of presentation",
        "status": "completed",
        "target_date": "2026-09-22",
        "outcome": "Diagnosis and stage by two weeks; PD-L1 at two weeks and tissue sequencing at three weeks; pembrolizumab started the day the sequencing was reviewed",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic diagnostic-timeliness goal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "GOAL-002",
        "display": "First palliative care visit within eight weeks of diagnosis",
        "status": "completed",
        "target_date": "2026-10-13",
        "outcome": "Seen by the palliative care team two weeks after diagnosis",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic ASCO 2017 integration goal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "GOAL-003",
        "display": "A voice strong enough for rehearsal by the second cycle",
        "status": "completed",
        "target_date": "2026-10-13",
        "outcome": "Louder, less breathy voice one week after injection medialization; light rehearsal resumed with voice therapy",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic work and voice goal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "GOAL-004",
        "display": "No grade 2 or higher immune-related adverse event missed: laboratory panel before each infusion and symptom review at each visit",
        "status": "completed",
        "target_date": "2026-10-13",
        "outcome": "Panels normal before cycles 1 and 2; no symptoms of colitis, pneumonitis, hepatitis, or endocrine dysfunction",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic safety-monitoring goal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "GOAL-005",
        "display": "Zoledronic acid started only after a dental examination and normal calcium and kidney function",
        "status": "completed",
        "target_date": "2026-10-13",
        "outcome": "Dental examination three weeks earlier; calcium 9.4 and eGFR 92; first dose with cycle 2",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic bone-agent safety goal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      }
    ],
    "interventions": [
      {
        "id": "INT-001",
        "display": "Thoracic oncology consultation for the tissue diagnosis, stage, biomarker plan, first-line therapy, the place of radiation and a bone-modifying agent, and monitoring",
        "status": "completed",
        "guideline_ids": [
          "GL-CMID-2026",
          "GL-NCCN-NSCLC-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic specialist consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "INT-002",
        "display": "Staging and tissue diagnosis: FDG PET-CT, brain MRI with contrast, and endobronchial ultrasound-guided needle aspiration of the highest-stage node, with enough tissue for PD-L1 and comprehensive next-generation sequencing, and plasma cell-free DNA testing in parallel",
        "status": "completed",
        "guideline_ids": [
          "GL-CMID-2026",
          "GL-NCCN-NSCLC-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic NCCN diagnostic and staging plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "INT-003",
        "display": "First-line systemic therapy chosen by biomarkers once sequencing excludes an actionable alteration: pembrolizumab 200 mg every 3 weeks for PD-L1 50 percent or more, with response CT every 6 to 12 weeks; switch to 400 mg every 6 weeks to fit the tour once stable",
        "status": "completed",
        "guideline_ids": [
          "GL-CMID-2026",
          "GL-NCCN-NSCLC-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic first-line treatment plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        },
        "recorded_date": "2026-09-15"
      },
      {
        "id": "INT-004",
        "display": "Immune-related adverse event monitoring: TSH and free T4, liver tests, creatinine, glucose, and blood count before each infusion; morning cortisol at baseline and for symptoms; written list of warning symptoms (diarrhea, cough or breathlessness, rash, yellowing, severe fatigue or headache) with a 24-hour oncology telephone line",
        "status": "completed",
        "guideline_ids": [
          "GL-ASCO-IRAE-2021",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic immunotherapy safety plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        },
        "recorded_date": "2026-09-15"
      },
      {
        "id": "INT-005",
        "display": "Early integrated palliative care alongside cancer treatment, starting within eight weeks of diagnosis, with symptom (ESAS) and distress screening at each visit and advance care planning",
        "status": "completed",
        "guideline_ids": [
          "GL-ASCO-PALL-2017",
          "GL-NCCN-DISTRESS-2026",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic palliative care plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        },
        "recorded_date": "2026-09-15"
      },
      {
        "id": "INT-006",
        "display": "If bone metastases are confirmed: zoledronic acid 4 mg every 12 weeks after a dental examination, with calcium and vitamin D and calcium and creatinine checks before each dose; palliative radiation only if a lesion becomes painful or threatens fracture",
        "status": "completed",
        "guideline_ids": [
          "GL-CMID-2026",
          "GL-NCCN-NSCLC-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic bone-health plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      },
      {
        "id": "INT-007",
        "display": "Voice and work: injection medialization of the left vocal fold, voice therapy with a speech-language pathologist, infusions scheduled on his day off, and a graded return to rehearsal and performance as he chooses",
        "status": "completed",
        "guideline_ids": [
          "GL-CMID-2026",
          "GL-NCCN-NSCLC-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic work-support plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        },
        "recorded_date": "2026-09-15"
      },
      {
        "id": "INT-008",
        "display": "Tobacco: confirm abstinence at each visit; no cessation treatment needed; record the smoking history for his care team",
        "status": "completed",
        "guideline_ids": [
          "GL-CMID-2026",
          "GL-NCCN-NSCLC-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0004"
          ],
          "synthetic_reason": "Synthetic tobacco plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T01:00:00-05:00"
        }
      }
    ],
    "guidelines": [
      {
        "guideline_id": "GL-CMID-2026",
        "title": "CMID: Clinical Monitoring Intelligence Database, lung cancer monograph",
        "publisher": "Aether Forge",
        "url": "https://patrickrutledge.github.io/topthirty/",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-NCCN-NSCLC-2026",
        "title": "NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer",
        "publisher": "National Comprehensive Cancer Network",
        "url": "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-ASCO-IRAE-2021",
        "title": "Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update",
        "publisher": "American Society of Clinical Oncology (Schneider BJ et al., J Clin Oncol 2021;39(36):4073-4126)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/34724392/",
        "version_or_year": "2021"
      },
      {
        "guideline_id": "GL-ASCO-PALL-2017",
        "title": "Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update",
        "publisher": "American Society of Clinical Oncology (Ferrell BR et al., J Clin Oncol 2017;35(1):96-112)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/28034065/",
        "version_or_year": "2017"
      },
      {
        "guideline_id": "GL-NCCN-DISTRESS-2026",
        "title": "NCCN Clinical Practice Guidelines in Oncology: Distress Management",
        "publisher": "National Comprehensive Cancer Network",
        "url": "https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-PREV-2026",
        "title": "Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements",
        "publisher": "Aether Forge",
        "url": "https://patrickrutledge.github.io/preventative_services/",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-USPSTF-AB",
        "title": "USPSTF A and B Recommendations",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-USPSTF-CRC-2021",
        "title": "Colorectal Cancer: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
        "version_or_year": "2021"
      },
      {
        "guideline_id": "GL-USPSTF-PROSTATE-2018",
        "title": "Prostate Cancer: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening",
        "version_or_year": "2018"
      },
      {
        "guideline_id": "GL-USPSTF-AAA-2019",
        "title": "Abdominal Aortic Aneurysm: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/abdominal-aortic-aneurysm-screening",
        "version_or_year": "2019"
      },
      {
        "guideline_id": "GL-USPSTF-DEP-2023",
        "title": "Depression and Suicide Risk in Adults: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-depression-suicide-risk-adults",
        "version_or_year": "2023"
      },
      {
        "guideline_id": "GL-CDC-IMZ-2026",
        "title": "Adult Immunization Schedule by Age",
        "publisher": "Centers for Disease Control and Prevention",
        "url": "https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html",
        "version_or_year": "2026"
      }
    ]
  },
  "review": {
    "schema_validation": {
      "status": "not_started",
      "notes": "Run scripts/build.ps1 -Conformance."
    },
    "clinical_review": {
      "status": "not_started",
      "notes": "Awaiting clinician review; check the stage, the biomarker sequence (therapy started only after tissue sequencing), the choice of pembrolizumab monotherapy, the immune-related adverse event monitoring, the rash evaluation at the sick visit, and the deviation recorded for the missed symptom screen at treatment start."
    },
    "provenance_review": {
      "status": "not_started",
      "notes": "The recent-death rule does not apply (died 1985). Historical claims come from UPI, TIME, Cancer Today (AACR), Biography.com, and Encyclopedia.com. Birth-date conflicts from his own accounts are recorded as rejected alternatives. No statement or health fact is attributed to his relatives or colleagues; the histology, stage, biomarkers, and treatment are synthetic."
    },
    "safe_messaging_review": {
      "status": "not_started",
      "notes": "Tobacco claims are marked sensitive; his death is recorded without detail; the anti-smoking message is quoted as published."
    }
  }
}
